Education
About Us
Working with TipRanks
Follow Us
Sanofi (SNYNF)
OTHER OTC:SNYNF
SNYNF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$91.81 - $123.67
Previous CloseN/A
Volume2.00
Average Volume (3M)39.89K
Market Cap
$121.68B
Enterprise Value$126.24B
Total Cash (Recent Filing)$7.99B
Total Debt (Recent Filing)€21.05B
Price to Earnings (P/E)21.1
Beta0.18
Next Earnings
Jul 31, 2025EPS Estimate
1.89Last Dividend Ex-Date
May 12, 2025Dividend Yield4.19%
Share Statistics
EPS (TTM)1.57
Shares Outstanding1,227,755,500
10 Day Avg. Volume101,788
30 Day Avg. Volume39,892
Financial Highlights & Ratios
PEG Ratio1.33
Price to Book (P/B)1.55
Price to Sales (P/S)0.00
P/FCF Ratio71.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$130.31Price Target Upside26.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
Sanofi News
Bulls Say, Bears Say
Bulls Say
Acquisition BenefitsSanofi's acquisition of BPMC boosts its rare disease franchise, providing a growth opportunity with Ayvakit, the only approved medicine for systemic mastocytosis.
Financial PerformanceThe acquisition of Blueprint Medicines is expected to enhance Sanofi's financial performance, being accretive to business operating income and EPS post-2026.
Product ExclusivityAyvakit benefits from Orphan Drug Exclusivity until 2030, extending its market potential and protecting it from price negotiation.
Bears Say
Competitive PressurePhase II competitor data indicates higher symptom reduction for a rival drug compared to Ayvakit, though with more significant safety concerns.
Regulatory ChallengesMixed data across trials raises debate over the regulatory path forward for itepekimab, complicating its potential approval.
Trial ResultsThe product failed to show a benefit in moderate to severe exacerbations in the second trial, suggesting potential delays in submission due to a lack of required positive trials.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
14.12% Mutual Funds
<0.01% Other Institutional Investors
70.49% Public Companies and
Individual Investors
SNYNF FAQ
What was Sanofi’s price range in the past 12 months?
Sanofi lowest stock price was $91.81 and its highest was $123.67 in the past 12 months.
What is Sanofi’s market cap?
Sanofi’s market cap is $121.68B.
When is Sanofi’s upcoming earnings report date?
Sanofi’s upcoming earnings report date is Jul 31, 2025 which is in 52 days.
How were Sanofi’s earnings last quarter?
Sanofi released its earnings results on Apr 24, 2025. The company reported $1.569 earnings per share for the quarter, missing the consensus estimate of $1.914 by -$0.345.
Is Sanofi overvalued?
According to Wall Street analysts Sanofi’s price is currently Undervalued.
Does Sanofi pay dividends?
Sanofi pays a Annually dividend of $4.485 which represents an annual dividend yield of 4.19%. See more information on Sanofi dividends here
What is Sanofi’s EPS estimate?
Sanofi’s EPS estimate is 1.89.
How many shares outstanding does Sanofi have?
Sanofi has 1,227,755,500 shares outstanding.
What happened to Sanofi’s price movement after its last earnings report?
Sanofi reported an EPS of $1.569 in its last earnings report, missing expectations of $1.914. Following the earnings report the stock price went up 0.5%.
Which hedge fund is a major shareholder of Sanofi?
Currently, no hedge funds are holding shares in SNYNF
Company Description
Sanofi
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
SNYNF Company Deck
SNYNF Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong sales growth, especially in Dupixent and the Vaccine business, supported by new product launches and improved financial metrics. However, challenges were noted in exchange rates, potential tariffs, and specific segments like respiratory development and the U.S. flu vaccine market.Read More>SNYNF Stock 12 Month Forecast
Average Price Target
$130.31
▲(26.51%Upside)